J M Cózar Olmo, J Carballido Rodriguez, P Luque Galvez, A G Tabernero Gómez, A Barreiro Mouro, E Sánchez Sánchez, C González Enguita, J Alcover García, E Garcia-Galisteo, J M Abascal García, M Sanchez Chapado, F GómezVeiga, R J Minguez Martínez, A Rodriguez Antolin, R A Medina López, M Rico Morales, F J Regadera Sejas, S Búcar Terrades, D Jamardo Gonzalez, R Gálvez
OBJECTIVES: To assess the effectiveness and tolerability of zoledronic acid in prostate cancer patients with bone metastases at the hormone-sensitive (HS) and hormone-independent (HI) stages. MATERIALS AND METHODS: A nationwide, observational, prospective, open and multi-centre trial was devised, with a total of 218 male patients diagnosed with prostate cancer at the HS stage (36%) or HI stage (64%) who were administered zoledronic acid (4 mg/IV/month for 6 months) in addition to their specific oncological treatment...
May 2008: Actas Urologicas Españolas